Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base
{{output}}
BPDCN is an aggressive myeloid malignancy characterized by unique expression of CD123, CD4, CD56, CD303, CD304, TCL1 and TCF4. The development of tagraxofusp, a CD123-directed cytotoxin, has revolutionized BPDCN treatment, especially for patients unfit for che... ...
